Role of Altered Metabolic Microenvironment in Osteolytic Metastasis
Open Access
- 5 June 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8, 435
Abstract
Metastatic bone disease is generally incurable and leads to pathological fractures, pain, hypercalcemia, spinal cord compression and decreased mobility. The skeleton is the major site of bone metastases from solid cancers, including breast and prostate carcinoma. Bone metastasis is facilitated by activation of bone-resorbing osteoclasts, terminally differentiated multinucleated cells formed by fusion from monocytic precursors. Cancer cells are known to produce specific factors that stimulate osteoclast differentiation and function. Of interest, cancer cells are also known to alter their own bioenergetics increasing the use of glycolysis for their survival and function. Such change in energy utilization by cancer cells would result in altered levels of cell-permeable metabolites, including glucose, lactate, and pyruvate. Osteoclast resorption is energy-expensive, and we have previously demonstrated that during differentiation osteoclasts actively adapt to their bioenergetics microenvironment. We hypothesize that altered bioenergetics state of cancer cells will also modify the bioenergetics substrate availability for the tissue-resident bone cells, potentially creating a favorable milieu for pathological osteolysis. The goals of this review are to analyze how metastasizing cancer cells change the availability of energy substrates in bone microenvironment; and to assess how the altered bioenergetics may affect osteoclast differentiation and activity.Keywords
Funding Information
- Canadian Institutes of Health Research
This publication has 104 references indexed in Scilit:
- Fast exchange fluxes around the pyruvate node: a leaky cell model to explain the gain and loss of unlabelled and labelled metabolites in a tracer experimentCancer & Metabolism, 2016
- The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulatorCancer Letters, 2015
- Molecular Actions of Ovarian Cancer G Protein-Coupled Receptor 1 Caused by Extracellular Acidification in BoneInternational Journal of Molecular Sciences, 2014
- An evolutionary perspective on the Crabtree effectFrontiers in Molecular Biosciences, 2014
- Role of amino acid transporters in amino acid sensingThe American Journal of Clinical Nutrition, 2014
- Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβPLOS ONE, 2013
- Targeting lactate metabolism for cancer therapeuticsJournal of Clinical Investigation, 2013
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In VivoCell Metabolism, 2013
- Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastasesCancer Letters, 2012
- Extracellular glutamate alters mature osteoclast and osteoblast functionsCanadian Journal of Physiology and Pharmacology, 2010